Drug
Iptcaopan
Iptcaopan: highest development phase Phase 3, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| Iptcaopan 200 mg NCT05795140 | Phase 3 | Atypical Hemolytic Uremic Syndrome |
Latest
No recent events.
Follow Iptcaopan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.